NYSEMKT: OGENOragenics Inc Stock
$0.18+0.00 (+0%)
Updated Apr 17, 2025
OGEN Price
$0.18
Fair Value Price
N/A
Market Cap
$3.76M
52 Week Low
$0.16
52 Week High
$3.43
P/E
-0.11x
P/B
-17.74x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$10.57M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
-7.95
Operating Cash Flow
-$9M
Beta
0.85
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
OGEN Overview
Oragenics, Inc. is a biopharmaceutical company, which focuses on the development of novel antibiotics and treatments against infectious disease and oral mucositis. The company is headquartered in Tampa, Florida and currently employs 12 full-time employees. The firm is focused on offering antibiotics against infectious disease and on developing treatments for oral mucositis. The company is engaged in developing its antibiotic product candidate, MU1140, as well as other homolog antibiotic product candidates; researching AG013 in connection with the treatment of Oral Mucositis; commercializing its ProBiora3 probiotic products, and has other product candidates for out licensing or partnering. MU1140 is an antibiotic that is produced by the parent of the SMaRT strain. ProBiora3 is a blend of three naturally occurring strains of beneficial bacteria, including Streptococcus oralis KJ3, Streptococcus uberis KJ2 and Streptococcus rattus JH145. LPT3-04 is a compound, which is consumed in the human diet in small amounts and results in dose-dependent weight loss in experimental animal models.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine OGEN's potential to beat the market
- OGEN doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
OGEN
RankedUnranked of 463
RankedUnranked of 463
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $2.61 | A | |
| $7.75 | A | |
| $16.85 | A |
Be the first to know about important OGEN news, forecast changes, insider trades & much more!
OGEN News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how OGEN scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
OGEN is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
OGEN is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
OGEN's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more OGEN due diligence checks available for Premium users.
Valuation
OGEN price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.11x
Industry
-177.72x
Market
27.98x
OGEN price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-17.74x
Industry
4.05x
OGEN's financial health
Profit margin
Revenue
$0.0
Net Income
-$3.3M
Profit Margin
0%
OGEN's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$1.5M
Liabilities
$1.7M
Debt to equity
-7.95
OGEN's short-term liabilities ($1.68M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
OGEN's short-term assets ($1.47M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
OGEN's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
OGEN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$2.0M
Investing
$0.0
Financing
-$260.9k
OGEN's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
OGEN vs Biotech Stocks
Oragenics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.